Valuation : IN8bio, Inc.

Market Cap 10.75M 9.27M 8.72M 7.94M 14.94M 1.02B 15.02M 103M 40.12M 519M 40.34M 39.47M 1.72B P/E 2026 *
-1x
P/E 2027 * -1.13x
Enterprise Value 10.75M 9.27M 8.72M 7.94M 14.94M 1.02B 15.02M 103M 40.12M 519M 40.34M 39.47M 1.72B EV / Sales 2026 *
-
EV / Sales 2027 * 13x
Free-Float
92.42%
Yield 2026 *
-
Yield 2027 * -
1 day-0.91%
1 week-6.84%
Current month-0.91%
1 month+5.31%
3 months-36.99%
6 months-35.88%
Current year-53.42%
1 week 0.96
Extreme 0.96
1.19
1 month 0.88
Extreme 0.88
1.3
Current year 0.88
Extreme 0.88
2.73
1 year 0.88
Extreme 0.88
2.73
3 years 0.88
Extreme 0.88
74.4
5 years 0.88
Extreme 0.88
285
10 years 0.88
Extreme 0.88
309.57
Manager TitleAgeSince
Chief Executive Officer 50 2015-10-31
Chief Tech/Sci/R&D Officer 72 2018-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap. Importance
5/27/26 Don

Director

-724,637 7.3589%
5/9/26 Free

Chairman

22,000 0.2234%
5/9/26 Free

Director

22,000 0.2234%
Change 5-day change 1-year change 3-year change Capi.($)
-0.91%-6.84%-50.68%-96.57% 10.75M
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.18%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.29%-5.63%-1.48%+532.58% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.06%-4.22%+35.58%+173.15% 26.31B
Weighted average by Cap. +0.16%-3.22%+41.21%+157.59%

Financials

2026 *2027 *
Net sales - 830K 716K 673K 613K 1.15M 78.75M 1.16M 7.96M 3.1M 40.06M 3.12M 3.05M 133M
Net income -20.67M -17.83M -16.77M -15.28M -28.74M -1.96B -28.89M -198M -77.18M -998M -77.62M -75.93M -3.31B -23.47M -20.24M -19.04M -17.35M -32.62M -2.23B -32.8M -225M -87.62M -1.13B -88.11M -86.2M -3.76B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
26-09-01 US$1.090 -0.91% 19,948
26-08-31 US$1.100 +6.28% 36,919
26-08-28 US$1.035 -0.48% 24,328
26-08-27 US$1.040 -12.24% 130,382
26-08-26 US$1.185 +1.28% 3,351
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.090USD
Average target price
6.250USD
Spread / Average Target
+473.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock